<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04780204</url>
  </required_header>
  <id_info>
    <org_study_id>IN-KR-320-6132</org_study_id>
    <nct_id>NCT04780204</nct_id>
  </id_info>
  <brief_title>Effectiveness of Antiviral Treatment in Cirrhotic Patients With Low-level Hepatitis B Virus DNA Levels</brief_title>
  <acronym>ATTACH</acronym>
  <official_title>A Multicenter, Open-label, Randomized Controlled Trial for the Effectiveness of Antiviral TreAtment in Cirrhotic Patients With Low-level Hepatitis B Virus DNA Levels (ATTACH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Evidence-Based Healthcare Collaborating Agency</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, Open-label, Randomized Controlled Trial Male and female adults with liver&#xD;
      cirrhosis due to chronic hepatitis B virus infection who have low-level viremia and are&#xD;
      beyond treatment indications by current guidelines.&#xD;
&#xD;
      To assess the efficacy of Tenofovir Alafenamide (TAF) in reducing liver-related events&#xD;
      (hepatocellular carcinoma, liver-related events and death, decompensated liver cirrhosis) in&#xD;
      cirrhotic chronic hepatitis B patients with low-level viremia beyond treatment indications by&#xD;
      current guidelines, compared with best supportive care&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial is a multicenter, open label, randomized controlled study in cirrhotic&#xD;
      chronic hepatitis B patients with low-level viremia beyond treatment indications by current&#xD;
      guidelines.&#xD;
&#xD;
      Approximately 400 subjects meeting eligibility criteria will be enrolled and randomized (1:1)&#xD;
      to Treatment Arm (A) or Observational Arm (B), as below:&#xD;
&#xD;
        -  Treatment Arm (A): 200 subjects, TAF 25mg once daily with food for 3 years&#xD;
&#xD;
        -  Observational Arm (B): 200 subjects, best supportive care for 3 years This study was&#xD;
           designed to randomly assign treatment groups to subjects in order to prevent biases that&#xD;
           may be intervened, and to increase comparability between the groups. Since HBeAg status&#xD;
           could affect the clinical outcome in the eligible subjects, randomization will be&#xD;
           stratified by HBeAg status (positive or negative) at screening at a 1:1 ratio by using&#xD;
           centralized stratified block randomization.&#xD;
&#xD;
      Both groups (i.e. Treatment Arm and Observational Arm) are scheduled to be followed up to 3&#xD;
      years. When subjects in the Observational Arm group meets the treatment indications by&#xD;
      current guidelines (HBV DNA ≥2,000 IU/mL or progressed to decompensated cirrhosis with&#xD;
      detectable HBV DNA level), antiviral treatment will be initiated.&#xD;
&#xD;
      The primary endpoint will be analyzed with Kaplan-Meier methods and compared by the log-rank&#xD;
      test between the two groups. Between-group comparisons of continuous or categorical baseline&#xD;
      characteristics will be conducted using Student's t-test, Chi-square test or Fisher's exact&#xD;
      test, as appropriate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 23, 2021</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2025</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cumulative incidence rate of composite clinical events</measure>
    <time_frame>From randomization the composite clinical events will be collected every 6weeks , assessed up to 36months</time_frame>
    <description>hepatocellular carcinoma, death, liver transplantation, decompensated liver cirrhosis defined as Child-Pugh score ≥8, liver cirrhosis-related complications,liver-related unexpected hospital admission</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence</measure>
    <time_frame>From randomization the composite clinical events will be collected every 1year , assessed up to 3years</time_frame>
    <description>death, hepatocellular carcinoma , Liver transplantation, decompensated liver cirrhosis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>Antiviral Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tenofovir Alafenamide 25mg once daily , Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Best supportive care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment</intervention_name>
    <description>Tenofovir Alafenamide 25 mg oral once daily</description>
    <arm_group_label>Antiviral Treatment</arm_group_label>
    <other_name>Tenofovir alafenamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Observation of Hepatitis B</intervention_name>
    <description>Best Supportive care</description>
    <arm_group_label>Observation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Willing and able to provide written informed consent prior to study entry&#xD;
&#xD;
          2. Age ≥40 years and ≤80 years at the time of screening&#xD;
&#xD;
          3. Chronic hepatitis B infection defined as HBsAg (+) or HBV DNA (+) for at least 6&#xD;
             months prior to the Screening visit, or medical records indication a chronic hepatitis&#xD;
             B virus infection by meeting all of the following criteria at the time of screening.&#xD;
             (1) HBsAg (+), (2) HBV DNA (+), and (3) HBcAb IgM (-)&#xD;
&#xD;
          4. Either HBeAg (+) or HBeAg (-)&#xD;
&#xD;
          5. Serum HBV DNA levels ≥20 IU/mL and &lt;2,000 IU/mL at the time of screening&#xD;
&#xD;
          6. Evidence of liver cirrhosis defined as meeting any of the following criteria:&#xD;
&#xD;
               -  Radiological evidence of liver cirrhosis by ultrasound, CT, or MRI&#xD;
&#xD;
               -  Platelet count &lt;150,000 /mm3&#xD;
&#xD;
               -  Presence of esophageal or gastric varices by endoscopy in 2 years before the&#xD;
                  timing of screening&#xD;
&#xD;
               -  Clinically significant portal hypertension&#xD;
&#xD;
               -  Fibroscan ≥12.0 kPa (if the test was done in 6 months before the time of&#xD;
                  screening)&#xD;
&#xD;
          7. Estimated creatinine clearance ≥30 ml/min (by calculation of creatinine clearance or&#xD;
             using the CKD-EPI equation)&#xD;
&#xD;
          8. Ability to comply with all study requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Confirmed known co-infection with HCV, HIV, or HDV&#xD;
&#xD;
          2. Current alcohol (60g/day) or substance abuse judged by the investigator that will&#xD;
             potentially interfere with subject compliance&#xD;
&#xD;
          3. Any history of, or current evidence of, clinical hepatic decompensation (e.g.,&#xD;
             ascites, encephalopathy, variceal hemorrhage, or Child-Pugh score of ≥8, with the&#xD;
             exception of Gilbert syndrome) in 1 year before the time of screening&#xD;
&#xD;
          4. Currently on or have received therapy with Interferon or immunosuppressant (including&#xD;
             systemic chemotherapy) within 12 months prior to the screening&#xD;
&#xD;
          5. Requirement for chronic use of systemic immunosuppressant including, but not limited&#xD;
             to, corticosteroid (prednisone equivalent of &gt;40 mg/day for &gt;2 weeks), azathioprine,&#xD;
             or monoclonal antibodies&#xD;
&#xD;
          6. Received solid organ or bone marrow transplant&#xD;
&#xD;
          7. History of severe, life-threatening or other significant sensitivity to any excipients&#xD;
             of the study drugs&#xD;
&#xD;
          8. Any other clinical conditions (cardiovascular, respiratory, neurologic, or renal&#xD;
             conditions) or prior therapy that, in the opinion of the investigator, would make the&#xD;
             subject unsuitable for the study or unable to comply with dosing requirements.&#xD;
&#xD;
          9. Currently on or have received antiviral treatment for ≥ 2 weeks within 6 months prior&#xD;
             to the screening&#xD;
&#xD;
         10. History or current evidence of hepatocellular carcinoma (HCC), or high α-fetoprotein&#xD;
             (AFP) &gt; 20 ng/mL. But, the patients with AFP &gt; 20 ng/mL can be enrolled if AFP shows&#xD;
             decreasing trend and there is no evidence of HCC by dynamic CT or MRI)&#xD;
&#xD;
         11. Malignancy other than hepatocellular carcinoma within the 5 years prior to screening,&#xD;
             with the exception of specific cancers that are cured by surgical resection (within 2&#xD;
             years prior to screening with confirmation of no evidence of disease). Subjects under&#xD;
             evaluation for possible malignancy are not eligible.&#xD;
&#xD;
         12. Concurrent enrollment in another clinical study for other type of antiviral treatment&#xD;
             for CHB or immune modulatory drug within 3 months prior to randomization,&#xD;
             participation to an observational (non-interventional) clinical studies or&#xD;
             interventional studies not using anti-HBV or immune modulatory drugs, or during the&#xD;
             follow-up period of an interventional study are not exclusion criteria.&#xD;
&#xD;
         13. Pregnant women, women who are breastfeeding or who believe they may wish to become&#xD;
             pregnant during the course of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young-Suk Lim, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Young-Suk Lim, PhD</last_name>
    <phone>82-2-3010-3190</phone>
    <email>limys@amc.seoul.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soo Young Park</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young-Suk Lim, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chung-Ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyung Joon Kim</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Konkuk University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>So Young Kwon</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ji Hoon Kim</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyung-Hee University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gi-Ae Kim</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wonseok Kang, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeong Hoon Lee</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neung-Hwa Park</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 1, 2021</study_first_submitted>
  <study_first_submitted_qc>March 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2021</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Young-Suk Lim</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

